21:41 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Cell culture and mouse studies suggest BRD4 inhibitors could help treat cetuximab-resistant squamous cell carcinoma of the head and neck (SCCHN). In two human cetuximab-resistant SCCHN cell lines, cetuximab plus...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
15:26 , Apr 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, in vitro and mouse studies identified a BRD4 inhibitor that could help treat CLL. In B cells isolated from patients, BRD4 levels were higher than in B cells from...
16:01 , Mar 26, 2018 |  BC Innovations  |  Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters that...
22:06 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Ataxia Patient sample and cell culture studies suggest a synthetic transcription elongation factor that induces FXN expression could help treat Friedreich’s ataxia. The synthetic molecule consists of a small molecule bromodomain containing 4 (BRD4) ligand...
18:57 , Oct 27, 2017 |  BC Week In Review  |  Company News

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct...
15:00 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Resverlogix raises C$87M in private placement

On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 million ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each...
21:59 , Oct 13, 2017 |  BC Extra  |  Financial News

Shenzhen Hepalink triples stake in Resverlogix

Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each unit consists of a...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...